DC Chemicals Limited
China
Product Name: GZ-793A
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

1356447-90-9

1356447-90-9 structure

Name: GZ-793A
Chemical Name: (2R)-3-{(2R,6S)-2,6-Bis[2-(4-methoxyphenyl)ethyl]-1-piperidinyl}-1,2-propanediol hydrochloride (1:1)
CAS Number: 1356447-90-9
Molecular Formula: C₂₆H₃₈ClNO₄
Molecular Weight: 464.037
Catalog: Signaling Pathways Membrane Transporter/Ion Channel Monoamine Transporter
Create Date: 2018-06-23 11:01:01
Modify Date: 2024-01-09 09:45:10
GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 µM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction[1][2][3].

Name	(2R)-3-{(2R,6S)-2,6-Bis[2-(4-methoxyphenyl)ethyl]-1-piperidinyl}-1,2-propanediol hydrochloride (1:1)
Synonyms	(2R)-3-{(2R,6S)-2,6-Bis[2-(4-methoxyphenyl)ethyl]-1-piperidinyl}-1,2-propanediol hydrochloride (1:1) 1,2-Propanediol, 3-[(2R,6S)-2,6-bis[2-(4-methoxyphenyl)ethyl]-1-piperidinyl]-, (2R)-, hydrochloride (1:1)

Description	GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 µM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction[1][2][3].
Related Catalog	Research Areas >> Neurological Disease Signaling Pathways >> Membrane Transporter/Ion Channel >> Monoamine Transporter
Target	Ki: 0.029 µM (VMAT2)[1].
In Vivo	GZ-793A (30, 60, 120 or 240 mg/kg; p.o.; once) decreases the number of METH infusions self-administered across each time interval evaluats in a dose-dependent manner[1]. GZ-793A (1-100 µM; 90 min) inhibits METH (5 µM)-evoked fractional dopamine releases[2]. Animal Model: Adult male Sprague-Dawley rats[1]. Dosage: 30, 60, 120 or 240 mg/kg Administration: Oral administration; once. Result: Decreased the number of METH infusions self-administered in a dose-dependent manner, and with an ~85% reduction at the highest dose (240 mg/kg). Decreased the METH self-administration produced by lasted at least 180 min. Animal Model: Male Sprague-Dawley rats (250–275 g; 9-week-old; 0.5 mm thick rats coronal striatal slices are used)[2]. Dosage: 1-100 µM Administration: 90 min Result: Inhibited methamphetamine-evoked dopamine released in a concentration-dependent manner.
References	[1]. Wilmouth CE, et al. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. Pharmacol Biochem Behav. 2013 Nov;112:29-33. [2]. Nickell JR, et al. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. Eur J Pharmacol. 2017 Jan 15;795:143-149. [3]. Nickell JR, et al. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol. 2014;69:71-106.

Molecular Formula	C₂₆H₃₈ClNO₄
Molecular Weight	464.037
Exact Mass	463.248932

Symbol	GHS09
Signal Word	Warning
Hazard Statements	H410
Precautionary Statements	P273-P501
RIDADR	UN 3077 9 / PGIII

1356447-90-9	82410-32-0
769-20-0	67014-36-2
172529-94-1	54422-45-6
23357-52-0	2217-40-5
172015-79-1	76272-35-0